Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

NUVA vs. RMD: Which Stock Is the Better Value Option?

ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany

ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.

Phibro (PAHC) Up 7.6% Since Last Earnings Report: Can It Continue?

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline

Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.

ResMed (RMD) Q3 Earnings and Revenues Lag Estimates

ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Here's Why You Should Retain ResMed (RMD) Stock for Now

ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.

ResMed (RMD) Q2 Earnings Meet Estimates

ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for ResMed (RMD) This Earnings Season?

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 9.2% in 4 Weeks, Here's Why You Should You Buy the Dip in ResMed (RMD)

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, 2022 View Up

Walgreens Boots' (WBA) revenues increased year over year in the fiscal first quarter, driven by COVID-19 vaccinations and testing.

Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.

ABT or RMD: Which Is the Better Value Stock Right Now?

ABT vs. RMD: Which Stock Is the Better Value Option?

Here's Why You Should Retain ResMed (RMD) Stock for Now

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

Smart Beta ETF report for RYH

ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.

ResMed (RMD) Q1 Earnings and Revenues Surpass Estimates

ResMed (RMD) delivered earnings and revenue surprises of 11.85% and 5.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?